Endolysins Active Against Staphylococcus Bacteria, Pharmaceutical Compositions, and Methods Relating Thereto
The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including isolated endolysin polypeptides from bacteriophage GRCS.
1 . A pharmaceutical composition for killing Gram-positive bacteria comprising an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or variants thereof having at least 80% identity thereto and effective for killing said bacteria, and a pharmaceutically acceptable carrier.
2 . The pharmaceutical composition of claim 1 , wherein said isolated polypeptide further comprises the amino acid sequence of SEQ ID NO: 7.
3 . The pharmaceutical composition of claim 1 , wherein said isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 5.
4 . The pharmaceutical composition of claim 1 , further comprising one or more antibiotic.
5 . The pharmaceutical composition of claim 4 , wherein said antibiotic is selected from the group consisting of a penicillin, a cephalosporin, a polymyxin, an ansamycin, a quinolone, a sulfonamide, a lipopeptide, a glycycline, and an oxazolidinone.
6 . The pharmaceutical composition of claim 4 , wherein said antibiotic is selected from the group consisting of linezolid, daptomycin, and tigecycline, vancomycin, fidaxomicin, and metronidazole.
7 . An isolated polypeptide capable of killing one or more strain of Staphylococcus bacteria, comprising the amino acid sequence of SEQ ID NO: 6 or variants thereof having at least 80% identity thereto and effective for killing said bacteria.
8 . The isolated polypeptide of claim 7 , further comprising the amino acid sequence of SEQ ID NO: 7.
9 . The isolated polypeptide of claim 7 , which comprises the amino acid sequence of SEQ ID NO: 5.
10 . A nucleic acid encoding the isolated polypeptide of claim 7 .
11 . A surface of a substrate comprising an antibacterial coating, said coating comprising an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or variants thereof having at least 80% identity thereto.
12 . The surface of claim 11 , wherein said isolated polypeptide further comprises the amino acid sequence of SEQ ID NO: 7.
13 . The surface of claim 11 , wherein said isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 5.
14 . The surface of claim 11 , wherein said coating further comprises one or more antibiotic.
15 . The surface of claim 14 , wherein said antibiotic is selected from the group consisting of a penicillin, a cephalosporin, a polymyxin, an ansamycin, a quinolone, a sulfonamide, a lipopeptide, a glycycline, and an oxazolidinone.
16 . The surface of claim 11 , wherein said substrate is a medical device.
17 . The surface of claim 11 , wherein said substrate is an implantable medical device.